We advised InnoCare Pharma in the placement of new shares

Davis Polk advised InnoCare Pharma Limited in its placement of 210,508,000 new shares, for an aggregate consideration of approximately HK$3.04 billion. 

Davis Polk also advised InnoCare Pharma Limited in connection with its HK$2.24 billion ($287 million) IPO in March 2020.

InnoCare Pharma is a clinical stage biopharmaceutical company committed to discovering, developing and commercializing potential best-in-class and/or first-in-class drugs for the treatment of cancer and autoimmune diseases. Led by a well-known management team of seasoned industry executives, it has built a biopharmaceutical platform with strong in-house R&D capabilities, with a vision to become a global biopharmaceutical leader that develops and delivers innovative therapies for patients worldwide.

The Davis Polk team included partner Yang Chu and associate Jenny Ho. All members of the Davis Polk team are based in the Hong Kong office.

Copy link to share post